Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi ...
Yesterday marked day one of the 2026 ASCO Genitourinary (GU) Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results